Intersect ENT (XENT) Tops Q2 EPS by 11c

Intersect ENT (NASDAQ: XENT) reported Q2 EPS of ($0.08), $0.11 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $24 million versus the consensus estimate of $22.61 million.

Cash, cash equivalents and short-term investments totaled $100.0 million as of June 30, 2017.

Outlook

The company expects to achieve revenue in the third quarter 2017 of $21.0-$21.5 million. For the full year 2017, the company is raising the revenue outlook to $91-$93 million from the prior guidance of $89-$91 million. The company continues to expect full year 2017 gross margin of approximately 84% and operating expenses in the range of $96-$98 million.

For earnings history and earnings-related data on Intersect ENT (XENT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance